secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0000950170-24-032514
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024
--------------------------------------------------------------------------------

- Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.
- Steven Closter appointed CCO effective March 18; leads commercial strategy for anticipated launches of revumenib and axatilimab.
- Closter received base salary $460K, 45% target bonus, option for 150K shares, PRSU of 25K units, and sign-on RSU of 9K units.
- Closter brings over 30 years biopharma commercial experience, previously VP at Sunovion/Sumitomo Pharma America and Forest Labs/Allergan.
- Company reaffirms on track for two first- and best-in-class product launches in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/0000950170-24-032514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017024032514/sndx-20240315.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-032514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer